News Pfizer targets $2.5bn more in cost savings Pfizer's second-quarter results update is headlined by news of an additional $2.5 billion in cost-cutting initiatives.
Oncology ASCO 26: Three strong Pfizer phase 3s, with Johanna Bendell Pharmaphorum caught up with Johanna Bendell, Pfizer’s chief development officer for oncology, to learn about what the company is bringing to ASCO.
News Will new data make Pfizer's Lorbrena a ‘no-brainer’ in early... Pfizer has taken a big step towards positioning Lorbrena as a worthy heir to its big-selling Xalkori drug in lung cancer, after beating its parent in a phase 3 trial.
News Novartis taps China's Abogen for autoimmunity TCE Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
